June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Effect of intravitreal dexamethasone implant (Ozurdex®) in the glycemic control of patients with diabetic macular edema.
Author Affiliations & Notes
  • Emilie Agard
    Ophthalmology, HIA Desgenettes, Lyon, France
  • Hussam El Chehab
    Ophthalmology, HIA Desgenettes, Lyon, France
  • Ygal Boujnah
    Ophthalmology, HIA Desgenettes, Lyon, France
  • Aurélie Russo
    Ophthalmology, HIA Desgenettes, Lyon, France
  • Jean Philippe Leberre
    Endocrinology, HIA Desgenettes, Lyon, France
  • Chantal Mounier
    Endocrinology, HIA Desgenettes, Lyon, France
  • Corinne Dot
    Ophthalmology, HIA Desgenettes, Lyon, France
  • Footnotes
    Commercial Relationships Emilie Agard, None; Hussam El Chehab, None; Ygal Boujnah, None; Aurélie Russo, None; Jean Philippe Leberre, None; Chantal Mounier, None; Corinne Dot, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 1754. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Emilie Agard, Hussam El Chehab, Ygal Boujnah, Aurélie Russo, Jean Philippe Leberre, Chantal Mounier, Corinne Dot; Effect of intravitreal dexamethasone implant (Ozurdex®) in the glycemic control of patients with diabetic macular edema.. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):1754.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate the effect of intravitreal dexamethasone implant (Ozurdex®) in the glycemic control of patients with diabetic macular edema.

Methods: Ten patients with diabetic macular edema received an intravitreal injection (IVI) of dexamethasone implant (DEX implant, Ozurdex®). Glycated haemoglobin (HbA1C) is analyzed before and three months after IVI. The real-time glycemic readings, throughout the day and night, during at least one week, are provided by a new medical device (Animas® Vibe, Novalab, Fr).<br /> The primary outcome analysis was the comparison of HbA1C test before and after IVI. Other data included: blood glucose average, the percentage of time spent higher, lower and in glycemic target, and standard deviation over the period.

Results: Analysis of blood glucose was performed on an average of 10 days +/-3. The level of HbA1C decreased of 0,23% after the IVI (NS). Mean blood glycemic levels are 155,6 +/- 30,3 mg/dl before IVI and 140,3 +/- 29,3 mg/dl after IVI (p>0,9999).<br /> Patients spent 69,65% of time in the glycemic target before IVI, and 79% after IVI (p>0,1). Patients spent 28,97% of time above the glycemic target before IVI and 17,83% after IVI (p>0,1). Patients spent 1,38% of time below the target before IVI and 3,17% after (p>0,1). No significant difference was found between extreme values of blood glucose after IVI: 321,6 mg/dl versus 292 mg/dl for the highest values, 62,4 mg/dl versus 61,67 mg/dl for the lower values.

Conclusions: A bad control of diabetes is identified as a risk factor for both the development and progression of diabetic macular edema. So, it seems important that IVI of dexamethasone implant have no impact on blood glucose levels in diabetic patients. To our knowledge, this is the first study that analyses the glycemic control in human after DEX implant IVI with a daily continuous glucose monitoring.<br /> In this preliminary study, the intravitreal dexamethasone implant doesn’t seem to influence the glycemic profile in patients with diabetic macular edema. These data are also important for the endocrinologists.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×